216 related articles for article (PubMed ID: 20473949)
1. MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells.
Srivastava MK; Bosch JJ; Wilson AL; Edelman MJ; Ostrand-Rosenberg S
Int J Cancer; 2010 Dec; 127(11):2612-21. PubMed ID: 20473949
[TBL] [Abstract][Full Text] [Related]
2. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
3. Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells.
Srivastava MK; Bosch JJ; Thompson JA; Ksander BR; Edelman MJ; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2008 Oct; 57(10):1493-504. PubMed ID: 18322683
[TBL] [Abstract][Full Text] [Related]
4. Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy.
Dissanayake SK; Thompson JA; Bosch JJ; Clements VK; Chen PW; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2004 Mar; 64(5):1867-74. PubMed ID: 14996751
[TBL] [Abstract][Full Text] [Related]
5. The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.
Thompson JA; Srivastava MK; Bosch JJ; Clements VK; Ksander BR; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2008 Mar; 57(3):389-98. PubMed ID: 17724589
[TBL] [Abstract][Full Text] [Related]
6. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response.
Godet Y; Fabre E; Dosset M; Lamuraglia M; Levionnois E; Ravel P; Benhamouda N; Cazes A; Le Pimpec-Barthes F; Gaugler B; Langlade-Demoyen P; Pivot X; Saas P; Maillère B; Tartour E; Borg C; Adotévi O
Clin Cancer Res; 2012 May; 18(10):2943-53. PubMed ID: 22407833
[TBL] [Abstract][Full Text] [Related]
7. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract][Full Text] [Related]
8. The induction of cytotoxic T lymphocytes against HLA-A locus-matched lung adenocarcinoma in patients with non-small cell lung cancer.
Yoshino I; Takenoyama M; Fujie H; Hanagiri T; Yoshimatsu T; Imabayashi S; Eifuku R; Ogami A; Yano K; Osaki T; Nakanishi R; Ichiyoshi Y; Nomoto K; Yasumoto K
Jpn J Cancer Res; 1997 Aug; 88(8):743-9. PubMed ID: 9330606
[TBL] [Abstract][Full Text] [Related]
9. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
[TBL] [Abstract][Full Text] [Related]
10. Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: Correlation of the quality of T cell responses with NSCLC subtype.
Palata O; Podzimkova Hradilova N; Mysiková D; Kutna B; Mrazkova H; Lischke R; Spisek R; Adkins I
Immunol Lett; 2020 Mar; 219():46-53. PubMed ID: 31931024
[TBL] [Abstract][Full Text] [Related]
11. Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma.
Raez LE; Cassileth PA; Schlesselman JJ; Padmanabhan S; Fisher EZ; Baldie PA; Sridhar K; Podack ER
Cancer Gene Ther; 2003 Nov; 10(11):850-8. PubMed ID: 14605671
[TBL] [Abstract][Full Text] [Related]
12. Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells.
Bosch JJ; Iheagwara UK; Reid S; Srivastava MK; Wolf J; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2010 Jan; 59(1):103-12. PubMed ID: 19557412
[TBL] [Abstract][Full Text] [Related]
13. Immunologic parameters as significant prognostic factors in lung cancer.
Nakamura H; Saji H; Ogata A; Hosaka M; Hagiwara M; Kawasaki N; Konaka C; Kato H
Lung Cancer; 2002 Aug; 37(2):161-9. PubMed ID: 12140139
[TBL] [Abstract][Full Text] [Related]
14. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen.
Kobayashi H; Wood M; Song Y; Appella E; Celis E
Cancer Res; 2000 Sep; 60(18):5228-36. PubMed ID: 11016652
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients.
Ohue Y; Eikawa S; Okazaki N; Mizote Y; Isobe M; Uenaka A; Fukuda M; Old LJ; Oka M; Nakayama E
Int J Cancer; 2012 Sep; 131(5):E649-58. PubMed ID: 22109656
[TBL] [Abstract][Full Text] [Related]
16. Endogenous CD4
Veatch JR; Jesernig BL; Kargl J; Fitzgibbon M; Lee SM; Baik C; Martins R; Houghton AM; Riddell SR
Cancer Immunol Res; 2019 Jun; 7(6):910-922. PubMed ID: 31043415
[TBL] [Abstract][Full Text] [Related]
17. CD80 expression in an HLA-A2-positive human non-small cell lung cancer cell line enhances tumor-specific cytotoxicity of HLA-A2-positive T cells derived from a normal donor and a patient with non-small cell lung cancer.
Bixby DL; Yannelli JR
Int J Cancer; 1998 Dec; 78(6):685-94. PubMed ID: 9833760
[TBL] [Abstract][Full Text] [Related]
18. Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2.
Neumann F; Wagner C; Stevanovic S; Kubuschok B; Schormann C; Mischo A; Ertan K; Schmidt W; Pfreundschuh M
Int J Cancer; 2004 Nov; 112(4):661-8. PubMed ID: 15382048
[TBL] [Abstract][Full Text] [Related]
19. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
20. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
